Torunn I Yock

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/673967/publications.pdf

Version: 2024-02-01

112 papers	5,055 citations	87888 38 h-index	95266 68 g-index
114 all docs	114 docs citations	114 times ranked	4135 citing authors

#	Article	IF	Citations
1	Posterior reversible encephalopathy syndrome and necrotizing enterocolitis in a pediatric patient with medulloblastoma and COVIDâ€19 infection. Pediatric Blood and Cancer, 2023, 70, .	1.5	1
2	Radiation Necrosis with Proton Therapy in a Patient with Aarskog-Scott Syndrome and Medulloblastoma. International Journal of Particle Therapy, 2022, 8, 58-65.	1.8	2
3	Variation in Proton Craniospinal Irradiation Practice Patterns in the United States: A Pediatric Proton Consortium Registry (PPCR) Study. International Journal of Radiation Oncology Biology Physics, 2022, 112, 901-912.	0.8	6
4	Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy. Neuro-Oncology, 2022, 24, 1010-1019.	1.2	7
5	Factors Associated With Acute Toxicity in Pediatric Patients Treated With Proton Radiation Therapy: A Report From the Pediatric Proton Consortium Registry. Practical Radiation Oncology, 2022, 12, 155-162.	2.1	5
6	RONC-14. Olfactory Perception During Proton Radiation and Differences in Frequency of Olfactory Perceptions Based on Proton Craniospinal Irradiation Technique for Pediatric Brain Tumor Patients.. Neuro-Oncology, 2022, 24, i179-i179.	1.2	0
7	Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience. Neuro-Oncology, 2022, 24, 2180-2189.	1.2	1
8	Brain tumors: Medulloblastoma, ATRT, ependymoma. Pediatric Blood and Cancer, 2021, 68, e28395.	1.5	21
9	Clinical outcomes in a large pediatric cohort of patients with ependymoma treated with proton radiotherapy. Neuro-Oncology, 2021, 23, 156-166.	1.2	7
10	A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2021, 109, 726-735.	0.8	29
11	Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration. International Journal of Radiation Oncology Biology Physics, 2021, 109, 220-230.	0.8	7
12	Intra-arterial chemotherapy for rhabdomyosarcoma. Pediatric Hematology and Oncology, 2021, 38, 391-396.	0.8	1
13	Clinical outcomes of pediatric patients with autism spectrum disorder and other neurodevelopmental disorders and intracranial germ cell tumors. Pediatric Blood and Cancer, 2021, 68, e28935.	1.5	4
14	Circulating Lymphocyte Counts Early During Radiation Therapy Are Associated With Recurrence in Pediatric Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1044-1052.	0.8	6
15	Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. Journal of Clinical Oncology, 2021, 39, 2276-2283.	1.6	31
16	Proton Therapy for Pediatric Ependymoma: Mature Results From a Bicentric Study. International Journal of Radiation Oncology Biology Physics, 2021, 110, 815-820.	0.8	27
17	Local Control For High-Grade Nonrhabdomyosarcoma Soft Tissue Sarcoma Assigned to Radiation Therapy on ARST0332: A Report From the Childrens Oncology Group. International Journal of Radiation Oncology Biology Physics, 2021, 110, 821-830.	0.8	8
18	Proton Radiation Therapy for Pediatric Craniopharyngioma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1480-1487.	0.8	27

#	Article	IF	Citations
19	Metabolic response as assessed by ¹⁸Fâ€fluorodeoxyglucose positron emission tomographyâ€computed tomography does not predict outcome in patients with intermediateâ€or highâ€risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer Medicine, 2021, 10, 857-866.	2.8	18
20	RADT-34. OLFACTORY PERCEPTION DURING PROTON RADIATION AND DIFFERENCES IN FREQUENCY OF OLFACTORY PERCEPTIONS BASED ON PROTON CRANIOSPINAL IRRADIATION TECHNIQUE FOR PEDIATRIC BRAIN TUMOR PATIENTS. Neuro-Oncology, 2021, 23, vi48-vi48.	1.2	0
21	A comparison study assessing neuropsychological outcome of patients with post-operative pediatric cerebellar mutism syndrome and matched controls after proton radiation therapy. Child's Nervous System, 2020, 36, 305-313.	1.1	11
22	An open invitation to join the Pediatric Proton/Photon Consortium Registry to standardize data collection in pediatric radiation oncology. British Journal of Radiology, 2020, 93, 20190673.	2.2	24
23	Prolongation of radiotherapy duration is associated with inferior overall survival in patients with pediatric medulloblastoma and central nervous system primitive neuroectodermal tumors. Pediatric Blood and Cancer, 2020, 67, e28558.	1.5	7
24	Assessing second cancer risk after primary cancer treatment with photon or proton radiotherapy. Cancer, 2020, 126, 3397-3399.	4.1	6
25	Radiation for pediatric low-grade gliomas: who will benefit and how late is soon enough?. Neuro-Oncology, 2020, 22, 1068-1069.	1.2	4
26	Modern Radiotherapy for Pediatric Brain Tumors. Cancers, 2020, 12, 1533.	3.7	50
27	The role of proton therapy in pediatric malignancies: Recent advances and future directions. Seminars in Oncology, 2020, 47, 8-22.	2.2	20
28	Long-term health-related quality of life in pediatric brain tumor survivors receiving proton radiotherapy at <4 years of age. Neuro-Oncology, 2020, 22, 1379-1387.	1.2	22
29	RONC-24. PROTON THERAPY FOR PEDIATRIC EPENDYMOMA: MATURE OUTCOMES FROM THE UNIVERSITY OF FLORIDA AND MASSACHUSETTS GENERAL HOSPITAL. Neuro-Oncology, 2020, 22, iii460-iii460.	1.2	0
30	GCT-37. PREVALENCE OF AUTISM SPECTRUM DISORDER AND OTHER NEURODEVELOPMENTAL DISORDERS IN PEDIATRIC PATIENTS WITH INTRACRANIAL GERM CELL TUMORS. Neuro-Oncology, 2020, 22, iii335-iii335.	1.2	0
31	Revisiting the Role of Radiation Therapy for Pediatric Low-Grade Glioma. Journal of Clinical Oncology, 2019, 37, 3335-3339.	1.6	21
32	Increased distance from a treating proton center is associated with diminished ability to follow patients enrolled on a multicenter radiation oncology registry. Radiotherapy and Oncology, 2019, 134, 25-29.	0.6	7
33	Increased local failure for patients with intermediateâ€risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group. Cancer, 2019, 125, 3242-3248.	4.1	55
34	Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. Nature Reviews Clinical Oncology, 2019, 16, 521-522.	27.6	3
35	Pediatric postoperative cerebellar cognitive affective syndrome follows outflow pathway lesions. Neurology, 2019, 93, e1561-e1571.	1.1	55
36	Patterns of proton therapy use in pediatric cancer management in 2016: An international survey. Radiotherapy and Oncology, 2019, 132, 155-161.	0.6	42

#	Article	IF	Citations
37	Proton beam therapy in pediatric oncology. Current Opinion in Pediatrics, 2019, 31, 28-34.	2.0	25
38	The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma. Cancer, 2019, 125, 290-297.	4.1	60
39	Patient Prioritization for Proton Beam Therapy in a Cost-neutral Payer Environment: Use of the Clinical Benefit Score for Resource Allocation. Cureus, 2019, 11, e5703.	0.5	1
40	Left hippocampal dosimetry correlates with visual and verbal memory outcomes in survivors of pediatric brain tumors. Cancer, 2018, 124, 2238-2245.	4.1	41
41	National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. International Journal of Radiation Oncology Biology Physics, 2018, 101, 152-168.	0.8	138
42	Brainstem Injury in Pediatric Patients With Posterior Fossa Tumors Treated With Proton Beam Therapy and Associated Dosimetric Factors. International Journal of Radiation Oncology Biology Physics, 2018, 100, 719-729.	0.8	55
43	American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1057-1066.	0.8	140
44	Estimated IQ Systematically Underestimates Neurocognitive Sequelae in Irradiated Pediatric Brain Tumor Survivors. International Journal of Radiation Oncology Biology Physics, 2018, 101, 541-549.	0.8	17
45	The Children's Oncology Group Radiation Oncology Discipline: 15ÂYears of Contributions to the Treatment of Childhood Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 860-874.	0.8	34
46	Rethinking reconsent when minors reach adult age in minimal risk studies. Pediatric Blood and Cancer, 2018, 65, e26731.	1.5	5
47	Executive functioning, academic skills, and quality of life in pediatric patients with brain tumors post-proton radiation therapy. Journal of Neuro-Oncology, 2018, 137, 119-126.	2.9	35
48	RONC-20. VERTEBRAL BODY GROWTH RETARDATION FOLLOWING PROTON CRANIOSPINAL RADIATION. Neuro-Oncology, 2018, 20, i178-i178.	1.2	0
49	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2018, 36, 2770-2777.	1.6	124
50	Endocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain Tumors. Journal of Clinical Oncology, 2018, 36, 2854-2862.	1.6	111
51	MBCL-47. OTOTOXICITY IN MEDULLOBLASTOMA SURVIVORS FOLLOWING PROTON RADIATION. Neuro-Oncology, 2018, 20, i127-i127.	1.2	0
52	NSRG-16. LESION LOCALIZATION IN POSTERIOR FOSSA SYNDROME. Neuro-Oncology, 2018, 20, i148-i149.	1.2	0
53	DIPG-23. BRAINSTEM RADIATION EXPOSURE CONFERS SUBSTANTIAL RISK OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) IN MEDULLOBLASTOMA SURVIVORS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. Neuro-Oncology, 2018, 20, i53-i53.	1.2	0
54	Performance/outcomes data and physician process challenges for practical big data efforts in radiation oncology. Medical Physics, 2018, 45, e811-e819.	3.0	17

#	Article	IF	Citations
55	The role of proton beam therapy in central neurocytoma: A single-institution experience. Practical Radiation Oncology, 2018, 8, e305-e311.	2.1	1
56	Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. Radiotherapy and Oncology, 2018, 128, 44-55.	0.6	46
57	An Update From the Pediatric Proton Consortium Registry. Frontiers in Oncology, 2018, 8, 165.	2.8	37
58	Cognitive and Adaptive Outcomes After Proton Radiation for Pediatric Patients With Brain Tumors. International Journal of Radiation Oncology Biology Physics, 2018, 102, 391-398.	0.8	56
59	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. Acta Neuropathologica Communications, 2018, 6, 67.	5.2	12
60	Quality of life in patients with protonâ€treated pediatric medulloblastoma: Results of a prospective assessment with 5â€year followâ€up. Cancer, 2018, 124, 3390-3400.	4.1	17
61	Evaluating Intensity Modulated Proton Therapy Relative to Passive Scattering Proton Therapy for Increased Vertebral Column Sparing in Craniospinal Irradiation in Growing Pediatric Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 37-46.	0.8	29
62	45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy. Pediatric Blood and Cancer, 2017, 64, e26540.	1.5	33
63	Analysis of patient outcomes following proton radiation therapy for retinoblastoma. Advances in Radiation Oncology, 2017, 2, 44-52.	1.2	12
64	A Clarion Call for Large-Scale Collaborative Studies of Pediatric Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 980-981.	0.8	23
65	Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report From the Children's Oncology Group. Pediatric Blood and Cancer, 2016, 63, 1152-1162.	1.5	26
66	Proton therapy for paediatric CNS tumours â€" improving treatment-related outcomes. Nature Reviews Neurology, 2016, 12, 334-345.	10.1	50
67	Proton beam therapy for medulloblastoma â€“ Author's reply. Lancet Oncology, The, 2016, 17, e174-e175.	10.7	6
68	Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncology, The, 2016, 17, 287-298.	10.7	263
69	Clinical Outcomes Among Children With Standard-Risk Medulloblastoma Treated With Proton and Photon Radiation Therapy: A Comparison of Disease Control and Overall Survival. International Journal of Radiation Oncology Biology Physics, 2016, 94, 133-138.	0.8	105
70	Assessing the radiation-induced second cancer risk in proton therapy for pediatric brain tumors: the impact of employing a patient-specific aperture in pencil beam scanning. Physics in Medicine and Biology, 2016, 61, 12-22.	3.0	34
71	Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma. Neuro-Oncology, 2016, 18, 881-887.	1.2	122
72	Incidence of CNS Injury for a Cohort of 111 Patients Treated With Proton Therapy for Medulloblastoma: LET and RBE Associations for Areas of Injury. International Journal of Radiation Oncology Biology Physics, 2016, 95, 287-296.	0.8	101

#	Article	IF	Citations
73	18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG).. Journal of Clinical Oncology, 2016, 34, 10549-10549.	1.6	9
74	Systematic difference between Estimated IQ (EIQ) and Full Scale IQ (FSIQ) in survivors irradiated for pediatric brain tumors.. Journal of Clinical Oncology, 2016, 34, 10557-10557.	1.6	0
75	Secondary Malignancy Risk Following Proton Radiation Therapy. Frontiers in Oncology, 2015, 5, 261.	2.8	65
76	Health-Related Quality of Life of Adolescent and Young Adult Survivors of Central Nervous System Tumors. Journal of Pediatric Oncology Nursing, 2015, 32, 385-393.	1.5	15
77	Cardiac and inflammatory biomarkers do not correlate with volume of heart or lung receiving radiation. Radiation Oncology, 2015, 10, 5.	2.7	16
78	Local Failure in Parameningeal Rhabdomyosarcoma Correlates With Poor Response to Induction Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 358-367.	0.8	18
79	Early Cognitive Outcomes Following Proton Radiation in Pediatric Patients With Brain and Central Nervous System Tumors. International Journal of Radiation Oncology Biology Physics, 2015, 93, 400-407.	0.8	110
80	Use of proton therapy for re-irradiation in pediatric intracranial ependymoma. Radiotherapy and Oncology, 2015, 116, 301-308.	0.6	68
81	Early results from Childrenâ€™s Oncology Group (COG) ARST08P1: Pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS).. Journal of Clinical Oncology, 2015, 33, 10015-10015.	1.6	6
82	HRQoL in medulloblastoma patients enrolled on a prospective phase II study of proton radiation.. Journal of Clinical Oncology, 2015, 33, e21029-e21029.	1.6	0
83	Evaluation of permanent alopecia in pediatric medulloblastoma patients treated with proton radiation. Radiation Oncology, 2014, 9, 220.	2.7	35
84	Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer, 2014, 120, 126-133.	4.1	141
85	A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study. Radiotherapy and Oncology, 2014, 113, 77-83.	0.6	97
86	Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiotherapy and Oncology, 2014, 113, 89-94.	0.6	93
87	Patterns of Failure After Proton Therapy in Medulloblastoma; Linear Energy Transfer Distributions and Relative Biological Effectiveness Associations for Relapses. International Journal of Radiation Oncology Biology Physics, 2014, 88, 655-663.	0.8	71
88	Protons, the brainstem, and toxicity: Ingredients for an emerging dialectic. Acta OncolÃ³gica, 2014, 53, 1279-1282.	1.8	25
89	Preliminary Results of a Phase II Trial of Proton Radiotherapy for Pediatric Rhabdomyosarcoma. Journal of Clinical Oncology, 2014, 32, 3762-3770.	1.6	117
90	Proton Radiation Therapy for the Treatment ofÂRetinoblastoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, 863-869.	0.8	46

#	Article	IF	Citations
91	Clinical Outcomes and Late Endocrine, Neurocognitive, and Visual Profiles of Proton Radiation for Pediatric Low-Grade Gliomas. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1060-1068.	0.8	166
92	The Pediatric Proton Consortium Registry: A Multi-institutional Collaboration in U.S. Proton Centers. International Journal of Particle Therapy, 2014, 1, 323-334.	1.8	16
93	Bifocal intracranial tumors of nongerminomatous germ cell etiology: diagnostic and therapeutic implications. Neuro-Oncology, 2013, 15, 955-960.	1.2	44
94	Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. Neuro-Oncology, 2013, 15, 1552-1559.	1.2	128
95	Incidence of Second Malignancies Among Patients Treated With Proton Versus Photon Radiation. International Journal of Radiation Oncology Biology Physics, 2013, 87, 46-52.	0.8	241
96	Cost-effectiveness analysis of proton versus photon therapy with respect to risk of growth hormone deficiency.. Journal of Clinical Oncology, 2013, 31, e17553-e17553.	1.6	0
97	Second non-ocular tumors among survivors of retinoblastoma treated with proton therapy.. Journal of Clinical Oncology, 2013, 31, 10018-10018.	1.6	0
98	Prospective Study of Health-Related Quality of Life for Children With Brain Tumors Treated With Proton Radiotherapy. Journal of Clinical Oncology, 2012, 30, 2079-2086.	1.6	101
99	Elevation of Prostaglandin E 2 in Lung Cancer Patients with Digital Clubbing. Journal of Thoracic Oncology, 2012, 7, 1877-1878.	1.1	14
100	Risk of Second Cancers After Photon and Proton Radiotherapy. Health Physics, 2012, 103, 577-585.	0.5	32
101	An evidence based review of proton beam therapy: The report of ASTROâ€™s emerging technology committee. Radiotherapy and Oncology, 2012, 103, 8-11.	0.6	212
102	Proton radiotherapy for rhabomyosarcoma: Preliminary results from a multicenter prospective study.. Journal of Clinical Oncology, 2012, 30, 9585-9585.	1.6	0
103	Proton Radiotherapy for Pediatric Bladder/Prostate Rhabdomyosarcoma: Clinical Outcomes and Dosimetry Compared to Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1367-1373.	0.8	94
104	Proton Radiotherapy for Pediatric Central Nervous System Germ Cell Tumors: Early Clinical Outcomes. International Journal of Radiation Oncology Biology Physics, 2011, 79, 121-129.	0.8	109
105	Radiation Therapy for Pediatric Central Nervous System Tumors. Journal of Child Neurology, 2009, 24, 1387-1396.	1.4	63
106	Proton Radiotherapy for Childhood Ependymoma: Initial Clinical Outcomes and Dose Comparisons. International Journal of Radiation Oncology Biology Physics, 2008, 71, 979-986.	0.8	191
107	Local Control in Pelvic Ewing Sarcoma: Analysis From INT-0091â€”A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2006, 24, 3838-3843.	1.6	139
108	Proton radiotherapy for orbital rhabdomyosarcoma: Clinical outcome and a dosimetric comparison with photons. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1161-1168.	0.8	153

#	Article	IF	Citations
109	The Effect of Delaying Radiation Therapy for Systemic Chemotherapy on Local-regional Control in Breast Cancer. Breast Cancer Research and Treatment, 2004, 84, 161-171.	2.5	13
110	Technology Insight: proton beam radiotherapy for treatment in pediatric brain tumors. Nature Clinical Practice Oncology, 2004, 1, 97-103.	4.3	78
111	Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics, 2002, 54, 420-426.	0.8	18
112	Multi-Institutional Data Collection and Analysis via the Pediatric Proton/Photon Consortium Registry. , 0, , .		0